GlaxoSmithKline Teams Up With Mammoth Biosciences on a CRISPR-Based COVID-19 Test

GlaxoSmithKline (NYSE: GSK) is working with Mammoth Biosciences to develop a CRISPR-based test for SARS-CoV-2, the coronavirus that causes COVID-19.

CRISPR is a gene-editing tool that's typically being used by companies and researchers aiming to develop cures for diseases. The system can edit DNA in a specific place by searching the DNA for a specific sequence, then cutting the DNA at that spot to make the edit.

Mammoth, on the other hand, is using CRISPR's ability to search for a specific DNA sequence to detect the presence of genes from the virus, then using the cutting as a reporter of a positive test.

Continue reading

Source Fool.com